Compare · LUCD vs WST
LUCD vs WST
Side-by-side comparison of Lucid Diagnostics Inc. (LUCD) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUCD and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $21.24B, about 109.9x LUCD ($193.2M).
- LUCD has been more active in the news (13 items in the past 4 weeks vs 7 for WST).
- WST has more recent analyst coverage (15 ratings vs 6 for LUCD).
- Company
- Lucid Diagnostics Inc.
- West Pharmaceutical Services Inc.
- Price
- $1.09+1.87%
- $300.70+1.05%
- Market cap
- $193.2M
- $21.24B
- 1M return
- -
- +18.93%
- 1Y return
- -
- +42.46%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 13
- 7
- Recent ratings
- 6
- 15
Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest LUCD
- PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
- SEC Form DEFA14A filed by Lucid Diagnostics Inc.
- SEC Form DEF 14A filed by Lucid Diagnostics Inc.
- Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
- Amendment: New insider Lee Victoria Tou-Ho claimed ownership of 650,000 shares (SEC Form 3)
- Lucid Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
- SEC Form 424B5 filed by Lucid Diagnostics Inc.
- Lucid Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
Latest WST
- Sr. VP & Chief HR Officer Favorite Annette F exercised 2,817 shares at a strike of $83.47 and sold $859,753 worth of shares (2,817 units at $305.20) (SEC Form 4)
- VP, Chief Accounting Officer Winters Chad exercised 896 shares at a strike of $173.22 and sold $269,399 worth of shares (896 units at $300.67) (SEC Form 4)
- West to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Reports First-Quarter 2026 Results
- West to Host First-Quarter 2026 Conference Call
- SEC Form 4 filed by Haugen Janet Brutschea
- West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity
- Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.